CMS’ Limited Resources Hinder Ability To Implement Value-Based Purchasing
This article was originally published in The Gray Sheet
The Centers for Medicare & Medicaid Services' inability to fairly and accurately determine the "value" of a new device could deter the agency from utilizing value-based purchasing to pay for new technologies, according to MedPAC staff member Chantal Worzala, PhD
You may also be interested in...
CMS should consider a new medical technology's cost as well as its impact on quality of life in setting Medicare payment rates, according to an expert panel convened by Project HOPE
The Medicare Payment Advisory Commission is finding that coverage and cost components in paying for new medical technologies cannot be easily separated
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker